Pregnancy Prevention Programmes in Pharmacovigilance

Purpose and Scope

A pregnancy prevention programme (PPP) is a structured set of risk-minimisation measures intended to prevent exposure of an embryo or fetus to a medicinal product with an identified or potential embryo-fetal risk, or to reduce harm if exposure may already have occurred. A PPP is not simply an educational campaign. It is a coordinated safety system in which information, prescribing conditions, pregnancy testing, contraception-related actions, dispensing controls and follow-up may be combined according to the product-specific risk.

The modern EU framework is set out in GVP Module XVI Rev. 3 and, specifically for embryo-fetal risk, GVP Module XVI Addendum I, adopted in August 2025 and legally effective from 29 August 2025. The Addendum replaced the older consultation-stage pregnancy-prevention guidance and provides the current framework for risk-minimisation measures addressing embryo-fetal exposure.

Its guiding principle is important: embryo-fetal risk minimisation should not unnecessarily compromise treatment of the patient's medical need where no suitable alternative exists. The aim is therefore not simply to prevent pregnancy at all costs; it is to manage reproductive risk proportionately while preserving clinically appropriate access to treatment.

Why Embryo-Fetal Risk Requires a Distinct Framework

Embryo-fetal harm differs from many other adverse drug reactions because the person taking the medicine and the developing embryo or fetus may be different individuals, the critical exposure window may begin before pregnancy is recognised, and risk may depend on pharmacokinetics, timing of conception, duration of exposure and biological mechanism.

Potential manifestations include congenital anomalies, miscarriage, embryo-fetal death, impaired growth, neonatal effects and developmental consequences. The relevant risk pathway may also involve paternal exposure in uncommon circumstances, for example where the active substance or a harmful level of it may be present in seminal fluid or where germ cells may be affected.

This complexity means that a pregnancy warning in the product information is not always enough. Where the risk is serious, preventable and clinically important, a coordinated programme may be needed to influence several steps before, during and after treatment.

Regulatory Framework

GVP Module XVI Addendum I

Addendum I provides guidance on risk-minimisation measures intended to prevent embryo-fetal exposure at conception or in utero and to minimise risk where exposure may have occurred. It identifies several potentially relevant patient populations, including individuals with reproductive potential, people who are or may be pregnant, selected male patients where paternal exposure is relevant, children or adolescents in relation to future reproductive potential, and in specific circumstances blood donors or carers.

The exact target population for an individual product depends on its reproductive-toxicity profile, pharmacology and conditions of use.

Binding product-specific conditions

The existence and exact components of a PPP are product-specific. They may be imposed through the marketing authorisation, a referral outcome or another binding regulatory decision. Where specific pregnancy testing, contraception, prescribing or dispensing conditions form part of those requirements, they are not optional recommendations.

GVP provides the general framework for selecting, implementing and evaluating measures; the binding obligation for a particular medicine comes from applicable law and the product's regulatory conditions.

Relationship with the RMP

The RMP should explain the embryo-fetal safety concern, the rationale for additional risk minimisation, the components of the programme and how effectiveness will be evaluated. The PPP should therefore be traceable to the safety specification and risk-minimisation plan rather than operating as a stand-alone administrative programme.

Defining the Reproductive Risk

Before selecting controls, the organisation should characterise what is known and uncertain about the risk. Relevant questions include:

• Is the concern based on human data, non-clinical data, pharmacology or a combination?
• Is the risk identified or potential?
• What outcomes are plausible or demonstrated?
• What exposure window is clinically relevant?
• How long does clinically relevant drug exposure persist after treatment stops?
• Is paternal exposure relevant?
• Can fetal risk be reduced by avoiding exposure, modifying timing or responding rapidly after exposure?

The answers determine which programme components are scientifically justified.

Target Populations

The shorthand phrase “women of childbearing potential” is often too imprecise for modern programme design. Addendum I uses a broader patient-centred framework based on reproductive potential and the mechanism of risk. The relevant population may include individuals who can become pregnant, people already pregnant, selected male patients, adolescents approaching reproductive potential or other groups depending on the exposure pathway.

The programme should define the target population operationally so that prescribers and dispensers can identify who is subject to which measures. Vague definitions create implementation inconsistency.

The Risk-Minimisation Logic

A useful PPP maps the pathway from treatment decision to possible embryo-fetal exposure:

identify reproductive risk → identify relevant patient → counsel → assess pregnancy status where required → establish contraception-related measures where required → prescribe under defined conditions → dispense under defined conditions → maintain prevention during the relevant risk window → act promptly if pregnancy occurs

Not every product requires every step. The programme should include only those measures justified by the risk and regulatory decision, but each included step should have a clear safety purpose.

Core Programme Components

A pregnancy prevention programme should be understood as a system of mutually supporting controls. Educational tools alone rarely define the programme. Depending on the product-specific regulatory decision, the programme may include patient and healthcare-professional education, pregnancy testing, contraception-related requirements, restrictions on prescribing or dispensing, treatment-duration controls, patient acknowledgement or dialogue tools, patient cards and arrangements for pregnancy exposure reporting and follow-up.

The scientific rationale for each component should be clear. If the risk can arise from conception during treatment and persists after the last dose because of a long elimination period, post-treatment contraception duration should reflect the product-specific pharmacology and regulatory wording. If pregnancy testing is required, the timing should correspond to the period in which a false sense of safety would create exposure risk. Controls should therefore be biologically and clinically connected to the risk rather than copied from another product's programme.

Counselling and informed decision-making

Counselling should explain the embryo-fetal risk, why pregnancy prevention is needed, what measures are required and what to do if pregnancy occurs or is suspected. The objective is informed and actionable understanding. A signed form, where used, can document a process but does not prove that the patient understood it.

Healthcare professionals also need to understand how programme requirements intersect with the patient's underlying disease. For some serious conditions, delaying treatment may itself cause harm. Current GVP guidance therefore emphasises balancing reproductive-risk prevention with the patient's medical needs.

Pregnancy testing

Testing requirements are product-specific. Where required, the programme should define the relevant test timing, acceptable test characteristics and relationship to treatment initiation, continuation or dispensing. Operational procedures should also address delayed results, uncertain results and situations where testing cannot be performed as expected.

A testing process is only effective if its result changes the treatment pathway. Recording that a test was ordered is not equivalent to confirming that the required result was available before the relevant prescribing or dispensing decision.

Contraception-related measures

Contraception requirements should follow the product-specific regulatory conditions and should account for the duration of embryo-fetal risk. The programme should avoid substituting generic organisational advice for approved regulatory wording.

Where contraceptive methods are discussed, the programme should recognise that suitability depends on the individual patient's circumstances and medical care. Pharmacovigilance governance should focus on ensuring the approved risk-minimisation instructions are communicated and implemented, not on creating independent clinical contraception rules outside the authorised framework.

Prescribing and dispensing controls

Some PPPs include limits on prescription duration, validity periods, dispensing intervals, confirmation of programme conditions or other controls intended to narrow the opportunity for uncontrolled exposure. These measures can create a stronger barrier than education alone, but they also add operational complexity and can affect access to treatment.

The organisation should therefore understand how each control operates in the real healthcare system. A requirement that cannot be executed reliably in local prescribing or pharmacy workflows may fail even if it is scientifically reasonable on paper.

Responsibilities Across the Care Pathway

The exact responsibilities of prescribers, pharmacists, nurses, patients and caregivers are product- and country-specific. The programme should make these interfaces explicit.

The prescriber may be responsible for confirming eligibility, counselling, testing and prescription conditions. The pharmacist may have a role in verifying dispensing conditions or reinforcing approved messages. The patient may need to follow contraception-related instructions, undergo testing, carry a card or report suspected pregnancy promptly. Other professionals may support counselling, monitoring or coordination.

From the MAH perspective, responsibility centres on implementing the approved risk-minimisation programme, maintaining controlled materials, tracking country implementation, evaluating effectiveness and escalating evidence that the programme is not achieving its objective.

Pregnancy Exposure Despite the Programme

No PPP can guarantee zero pregnancies. When exposure occurs, the response should be clinically and pharmacovigilance appropriate rather than framed automatically as proof of individual non-compliance.

The programme should provide clear instructions for what the patient and healthcare professional should do. Pharmacovigilance processes should support capture of relevant exposure details, timing, dose, pregnancy course and outcome where available and permitted. Follow-up should be proportionate, respectful and compliant with data-protection requirements.

A pregnancy exposure can also provide information about a programme failure pathway. For example, the patient may not have received counselling, may have misunderstood the risk window, may have faced access barriers to the required preventive measure, or may have become pregnant despite adherence. Root-cause analysis should avoid assuming a single explanation before the facts are known.

Effectiveness Evaluation

The effectiveness question for a PPP is ultimately whether preventable embryo-fetal exposure is being minimised. Because pregnancy exposure may be rare, evaluation often requires several complementary measures.

Implementation measures

These can assess whether eligible healthcare professionals and patients receive the required tools, whether testing or counselling processes are available and whether programme materials are implemented in each country.

Knowledge and behavioural measures

Surveys can assess understanding of the reproductive risk and required actions. Drug utilisation studies can evaluate prescribing to people with reproductive potential, treatment initiation patterns, testing where measurable, prescription duration or other behaviours. GVP Module XVI Addendum I specifically recognises DUS as a possible tool for examining prescribing and adherence to risk-minimisation measures.

Pregnancy exposure and outcome data

Observed pregnancy exposures are clinically important but are difficult to interpret as a simple rate unless the denominator, ascertainment process and reporting completeness are understood. Changes over time can be influenced by treatment uptake, patient mix and awareness of reporting. Exposure data should therefore be interpreted together with utilisation and implementation information.

Success Criteria and Escalation

Effectiveness criteria should be defined prospectively where appropriate. A programme that repeatedly misses its targets should trigger a structured evaluation of why. Possible responses may include clearer materials, different distribution pathways, stronger prescribing controls, additional healthcare-professional engagement or regulatory discussion. The response should be tailored to the failure mechanism.

Simply intensifying the same intervention without understanding why it failed is poor risk-management practice.

Special Situations

Paternal exposure

Paternal risk is not assumed for every embryo-fetal safety concern. GVP Module XVI Addendum I recognises that, in uncommon situations, risk-minimisation measures may be relevant for male patients where seminal fluid may contain potentially harmful levels of the medicinal product or where semen or germ cells may be adversely affected. Product-specific evidence and regulatory wording determine whether such measures are required.

Adolescents and future reproductive potential

Some medicines are used in children or adolescents before reproductive potential is established. Where embryo-fetal risk could become relevant during longer-term treatment, the programme may need age-appropriate education and transition controls so that reproductive-risk measures begin at the clinically relevant time rather than only after an adult-care transfer.

Blood donation and indirect exposure pathways

The 2025 Addendum also recognises that, for certain products, blood donation may be relevant if exposure of a pregnant recipient could create risk. This is not a routine PPP component; it should be used only where scientifically and regulatorily justified for the individual medicine.

Treatment when no suitable alternative exists

A patient may require a medicine despite significant reproductive risk because alternative therapy is unsuitable or ineffective. The programme should support informed clinical decision-making rather than create an automatic barrier disconnected from medical need. This is one reason the current GVP framework emphasises patient-centred proportionality.

Governance and Lifecycle Management

A PPP typically spans pharmacovigilance, regulatory affairs, medical functions, affiliates, supply and external healthcare systems. Governance should preserve one controlled interpretation of the regulatory requirement while allowing country-specific implementation where necessary.

The organisation should maintain traceability for:

• the current regulatory basis of the programme;
• approved materials and country versions;
• pregnancy-testing, prescribing and dispensing requirements where applicable;
• local implementation status;
• programme deviations or implementation problems;
• effectiveness study protocols and results;
• pregnancy-exposure evidence relevant to the programme;
• decisions to revise, strengthen or simplify measures.

A change to the reproductive-risk profile should trigger an impact assessment across the entire programme, not only revision of a patient leaflet.

Potential Failure Modes

Illustrative failure modes include:

• treating a PPP as an educational-material distribution exercise;
• using vague definitions of the population subject to programme controls;
• applying pregnancy testing at a time that does not protect the relevant exposure window;
• assuming a test was completed because it was ordered;
• allowing prescription or dispensing controls to differ from the approved conditions without regulatory justification;
• failing to account for the post-treatment risk period;
• interpreting every pregnancy exposure as patient non-compliance without investigating the pathway;
• using pregnancy counts without a meaningful denominator to claim effectiveness;
• allowing country implementation to drift from the centrally approved programme;
• failing to act when effectiveness data show that the intended behaviour is not occurring.

These are illustrative operational risks, not asserted inspection findings.

Inspection Considerations

An inspector may examine whether the organisation can connect the embryo-fetal safety concern to the actual controls operating in each country. Evidence may include RMP commitments, regulatory decisions, approved materials, local implementation records, version histories, effectiveness protocols, DUS outputs, pregnancy-exposure follow-up and governance decisions.

Illustrative questions include:

• What evidence defines the reproductive-risk window?
• Which patients are subject to which controls, and how are they identified?
• How does the organisation know pregnancy testing or other required steps occur at the correct time?
• Are prescribing and dispensing controls implemented consistently with the regulatory decision?
• How are suspected programme failures investigated?
• What measures demonstrate effectiveness beyond distribution?
• How are findings reflected in the RMP and benefit-risk assessment?

The inspection focus is therefore not merely whether a PPP document exists, but whether the programme functions as an effective and traceable safety system.

Practical Checklist

A robust PPP should have:

• a clearly characterised embryo-fetal risk;
• a defined target population and exposure window;
• product-specific controls justified by the risk mechanism;
• approved counselling and educational tools;
• pregnancy testing, contraception, prescribing or dispensing requirements implemented exactly where required;
• a process for suspected or confirmed pregnancy exposure;
• country-level implementation control;
• prospectively planned effectiveness evaluation;
• governance for escalation and lifecycle revision.

Key Takeaways

Pregnancy prevention programmes are among the most complex forms of additional risk minimisation because they combine scientific, clinical, behavioural and regulatory controls across the treatment lifecycle. They should not be reduced to a checklist of standard measures copied from another product.

The current EU framework is GVP Module XVI Rev. 3 together with the final 2025 Module XVI Addendum I on embryo-fetal risks and Module XVI Addendum II on effectiveness evaluation. The programme should be proportional to the product-specific risk, preserve medically necessary access to treatment, and demonstrate through appropriate evidence that the intended exposure-prevention pathway is functioning.

References

1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module XVI – Risk minimisation measures (Rev. 3). EMA/204715/2012 Rev. 3, 26 July 2024. Legal effective date 6 August 2024.
2. European Medicines Agency. GVP Module XVI Addendum I – Risk minimisation measures for medicinal products with embryo-fetal risks. EMA/608947/2021, 22 August 2025. Legal effective date 29 August 2025.
3. European Medicines Agency. GVP Module XVI Addendum II – Methods for evaluating effectiveness of risk minimisation measures. EMA/419982/2019. Legal effective date 6 August 2024.
4. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems. Current version.
5. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VIII – Post-authorisation safety studies (Rev. 3). EMA/813938/2011 Rev. 3. Legal effective date 13 October 2017.
6. Directive 2001/83/EC, as amended, and Regulation (EC) No 726/2004, as amended.

Regulatory Note

Pregnancy-prevention requirements are product-specific. The existence, scope and exact components of a PPP must be determined from the current marketing authorisation, RMP, regulatory decision and national implementation requirements. This article describes the EU framework and should not be used to infer that a particular pregnancy test, contraception method, prescribing restriction or dispensing interval applies to a medicine unless that requirement is confirmed in the relevant regulatory documentation.